Clinical Trial

A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this intervention study is to evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HXN5003 in Healthy Participants.The main parameters it aims to answer are: 1. Does a single dose of HXN5003 in healthy participants impact the safety, tolerability and pharmacokinetic profiles? 2. Will immunogenicity of HXN5003 in healthy participants be altered? This study will be compared against a Placebo which contains the same inactive ingredients as those of HXN5003, but without the active ingredient.
Trial Details
NCT Number NCT07549750
Lead Sponsor Helixon Biotechnology (Suzhou) Co., Ltd
Conditions Atopic Dermatitis
Enrollment 28 participants
Start Date 2026-05-27
Primary Completion 2027-03-18 (estimated)
Study Completion 2027-04-16 (estimated)
Updated on ClinicalTrials.gov 2026-04-24